B-ALL-话题@MedSci

#B-ALL#

19篇内容 | 1900人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1423256, encodeId=d22814232560d, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：IKAROS和CK2调控高危型B-ALL的BCL-XL表达和化疗敏感性, objectType=article, longId=195267, objectId=dea919526ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dea919526ed5, replyNumber=0, likeNumber=72, createdTime=2020-06-05, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dea919526ed5, moduleTitle=Blood：IKAROS和CK2调控高危型B-ALL的BCL-XL表达和化疗敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dea919526ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423255, encodeId=c81e14232559a, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：B-ALL超二倍体细胞有丝分裂和染色体缺陷的分子机制, objectType=article, longId=193404, objectId=740319340482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=740319340482, replyNumber=0, likeNumber=71, createdTime=2020-05-04, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=740319340482, moduleTitle=Blood：B-ALL超二倍体细胞有丝分裂和染色体缺陷的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=740319340482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423254, encodeId=235c1423254f2, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：减小低复发风险B-ALL患儿的化疗强度可改善预后, objectType=article, longId=187701, objectId=053a18e70172, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053a18e70172, replyNumber=0, likeNumber=88, createdTime=2020-02-10, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053a18e70172, moduleTitle=Blood：减小低复发风险B-ALL患儿的化疗强度可改善预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=053a18e70172)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423253, encodeId=b034142325332, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL, objectType=article, longId=185565, objectId=07da185565a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07da185565a3, replyNumber=0, likeNumber=134, createdTime=2020-01-03, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07da185565a3, moduleTitle=Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07da185565a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423252, encodeId=c28a14232528e, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL, objectType=article, longId=181713, objectId=584d181e139f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=584d181e139f, replyNumber=0, likeNumber=84, createdTime=2019-10-23, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=584d181e139f, moduleTitle=Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=584d181e139f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423251, encodeId=b93d1423251e7, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？, objectType=article, longId=130441, objectId=33e2130441cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e2130441cc, replyNumber=0, likeNumber=68, createdTime=2018-02-25, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e2130441cc, moduleTitle=Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e2130441cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423250, encodeId=f296142325071, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=Blood：通过高通量测序检测残留病灶，可改善儿童B-ALL的危险分层。, objectType=article, longId=125159, objectId=354412515978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=354412515978, replyNumber=0, likeNumber=115, createdTime=2018-01-01, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=354412515978, moduleTitle=Blood：通过高通量测序检测残留病灶，可改善儿童B-ALL的危险分层。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=354412515978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423249, encodeId=211b14232497f, content=<a href='/topic/show?id=18f43131be' target=_blank style='color:#2F92EE;'>#B-ALL#</a>, objectTitle=J Clin Oncol：高危B-ALL患者来说，接受大剂量甲氨蝶呤治疗可更好地改善其生存率, objectType=article, longId=74192, objectId=da19e419235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da19e419235, replyNumber=0, likeNumber=48, createdTime=2016-08-02, rootId=0, userName=chenzhuanggui, userId=7c123763345, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da19e419235, moduleTitle=J Clin Oncol：高危B-ALL患者来说，接受大剂量甲氨蝶呤治疗可更好地改善其生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da19e419235)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B-ALL

2020-05-29

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：IKAROS和CK2调控高危型B-ALL的BCL-XL表达和化疗敏感性

2020-06-05

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：B-ALL超二倍体细胞有丝分裂和染色体缺陷的分子机制

2020-05-04

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：减小低复发风险B-ALL患儿的化疗强度可改善预后

2020-02-10

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL

2020-01-03

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：CD19特异性CAR T细胞疗法治疗R/R B-ALL

2019-10-23

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Leukemia：难治性或复发性B-ALL：低剂量CD19-CAR-T细胞疗法有效吗？

2018-02-25

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

Blood：通过高通量测序检测残留病灶，可改善儿童B-ALL的危险分层。

2018-01-01

chenzhuanggui (审核中...)

前往app查看评论内容

#B-ALL#

J Clin Oncol：高危B-ALL患者来说，接受大剂量甲氨蝶呤治疗可更好地改善其生存率

2016-08-02

科室
- - 订阅+
  - 更多科室
工具
服务